Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.31 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL856097 | 0.76 | OPRM1 (0.40) | OPRM1OPRD1OPRK1HCAR3HCAR2 | |
| SCHEMBL23706677 | 0.71 | OPRM1 (0.34) | OPRM1OPRD1OPRK1 | |
| SCHEMBL9386145 | 0.70 | OPRM1 (0.37) | OPRM1OPRD1OPRK1ENPP2 | |
| SCHEMBL361976 | 0.66 | CHRNB2 (0.39) | OPRD1ALOX5SLC6A4SLC6A3 | |
| SCHEMBL16344886 | 0.65 | ALOX5 (0.42) | OPRM1OPRD1OPRK1ALOX5ENPP2 | |
| SCHEMBL6026181 | 0.65 | ALOX5 (0.60) | ALOX5 | |
| SCHEMBL25865053 | 0.65 | DRD2 (0.44) | ENPP2 | |
| SCHEMBL8403957 | 0.65 | SLC6A4 (0.43) | OPRM1HCAR3HCAR2ALOX5SLC6A4 | |
| SCHEMBL25865230 | 0.64 | OPRM1 (0.34) | OPRM1OPRD1OPRK1ALOX5ENPP2 | |
| SCHEMBL27899553 | 0.63 | TSHR (0.38) | OPRM1OPRK1CYP26A1CYP26B1HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227465-A1 | METHOD FOR EVALUATING QUALITY OF (3S)-3-(4-(3-(1,4-DIOXASPIRO[4,5]DEC-7-EN-8-YL)BENZYLOXY)PHENYL)HEX-4-INOIC ACID | HYUNDAI PHARM CO., LTD. (KR) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227465-A1 | METHOD FOR EVALUATING QUALITY OF (3S)-3-(4-(3-(1,4-DIOXASPIRO[4,5]DEC-7-EN-8-YL)BENZYLOXY)PHENYL)HEX-4-INOIC ACID | ITPR2, IPO7, IPO4 | OPRM1 1135/4885OPRD1 762/4885OPRK1 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.